Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Quest Pharmatech, Inc. V.QPT

Alternate Symbol(s):  QPTFF

Quest PharmaTech Inc is a Canadian based pharmaceutical company developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target- truncated O-glycans on MUC16 discovered at University of Nebraska Medical Center. The company is also developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications.


Stock Price Chart (TSXV:QPT)

Fundamentals Snapshot (TSXV:QPT)

Current News (TSXV:QPT)

Quest PharmaTech Provides Corporate Update

Canada NewsWire April 19, 2022

OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer

PR Newswire September 1, 2021

Quest PharmaTech Announces Results from AGM

PR Newswire July 7, 2021

Quest PharmaTech announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American Association of Clinical Oncologists

Canada NewsWire June 1, 2021

Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.

Canada NewsWire March 26, 2021

Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.

Canada NewsWire February 2, 2021

Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.

Canada NewsWire January 5, 2021

Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company's Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer and appoints Dr. Sunil Gupta as Chief Medical Officer

Canada NewsWire November 9, 2020

Quest Provides Corporate Update

Canada NewsWire June 4, 2020

Opinion & Analysis (TSXV:QPT)

No current opinion is available.

Bullboard Posts (TSXV:QPT)

Bozo the clown

the clown ....Just lost $quick trying to run this up, lol
bigstar10 - May 30, 2022

RE:RE:RE:RE:RE:Zero news

"Company reported a net loss of $85,038,575 during the year ended January 31, 2022" This is a superficial loss due to the...
G1945V - May 27, 2022

Interesting

https://clinicaltrials.gov/ct2/show/study/NCT04498117#contactlocation Updated today; There's a 154 Locations recruting now. They...
ARIMA11 - May 27, 2022

RE:RE:RE:RE:Zero news

Financial are out and its definitely not pretty! Basic income (loss) / share at Jan 31 22 (-0.50) vs. Jan 31 2021 (+1.13) is interesting...
ARIMA11 - May 26, 2022

RE:RE:RE:Zero news

What other choice do we have? G1945V
G1945V - May 26, 2022

RE:RE:Zero news

A phase III cancer immunotherapy program in clinical trials currently and a SP that has been 0.10 or so for several years. Hello? Fate in...
PosNeg1 - May 25, 2022